• K Chris Min, Tiffany Woo, Christopher Assaid, Jacqueline McCrea, Deborah M Gurner, Sisk Christine McCrary CM Merck & Co, Inc., Kenilworth, NJ, USA., Franklin Adkinson, and W Joseph Herring.
• Merck & Co, Inc., Kenilworth, NJ, USA. Electronic address: kwan-hong.chris.min@merck.com.
• J Clin Anesth. 2018 Jun 1; 47: 67-73.

Study ObjectiveTo evaluate the incidence of hypersensitivity and anaphylaxis after administration of sugammadex.DesignRetrospective analysis.SettingSugammadex clinical development program and post-marketing experience.PatientsSurgical patients and healthy volunteers who received sugammadex or placebo/comparator with anesthesia and/or neuromuscular blockade (NMB).InterventionsSugammadex administered as 2.0 mg/kg at reappearance of the second twitch, 4.0 mg/kg at 1-2 post-tetanic count, or 16.0 mg/kg at 3 min after rocuronium 1.2 mg/kg.MeasurementsThree analytical methods were used: 1) automated MedDRA queries; 2) searches of adverse events (AEs) consistent with treatment-related hypersensitivity reactions as diagnosed by the investigator; and 3) a retrospective adjudication of AEs suggestive of hypersensitivity by a blinded, independent adjudication committee (AC). In addition, a search of all post-marketing reports of events of hypersensitivity was performed, and events were retrospectively adjudicated by an independent AC. Anaphylaxis was determined according to Sampson Criterion 1.Main ResultsThe pooled dataset included 3519 unique subjects who received sugammadex and 544 who received placebo. The automated MedDRA query method showed no apparent increase in hypersensitivity or anaphylaxis with sugammadex as compared to placebo or neostigmine. Similarly, there was a low overall incidence of AEs of treatment-related hypersensitivity (<1%), with no differences between sugammadex and placebo or neostigmine. Finally, the retrospective adjudication of AEs suggestive of hypersensitivity showed a low incidence of hypersensitivity (0.56% and 0.21% for sugammadex 2 mg/kg and 4 mg/kg, respectively), with an incidence similar to subjects who received placebo (0.55%). There were no confirmed cases of anaphylaxis in the pooled studies. During post-marketing use, spontaneous reports of anaphylaxis occurred with approximately 0.01% of sugammadex doses.ConclusionsSubjects who received sugammadex with general anesthesia and/or NMB had a low overall incidence of hypersensitivity, with no apparent increase in hypersensitivity or anaphylaxis with sugammadex as compared to placebo or neostigmine.Copyright © 2018 Elsevier Inc. All rights reserved.

39 keywords...

hide…